Skip to main content
. Author manuscript; available in PMC: 2023 Jun 9.
Published in final edited form as: Neuropharmacology. 2021 Nov 3;202:108870. doi: 10.1016/j.neuropharm.2021.108870

Table 3.

aSyn-directed Immunotherapy Clinical Trials.

Active/Passive
Immunotherapy		 Compound Route of
Administration		 Mechanism Findings Effect on α-syn References
Active PD01A/AFFiRiS Subcutaneous injection Mimics α-syn C-terminal; acts as B cell epitope Completed; safe and tolerable ↓ CSF α -syn oligomers; IgG antibody response to α-syn epitope Volc et al. (2020)
Active PD03A/AFFiRiS Subcutaneous injection Mimics α-syn C-terminal; acts as B cell epitope Completed; safe and tolerable Sustained IgG antibody response to α-syn epitope Poewe et al. (2021)
Passive PRX002/RG7935 (Prasinezumab)/Prothena Biosciences Limited Intravenous infusion Targets α-syn C-terminal to halt α-syn neuronal transmission Completed; safe and well tolerated; Phase II is ongoing Reduced free serum α-syn Jankovic et al. (2018)
Passive BIIB054 (Cinpanemab)/Biogen Intravenous infusion Targets aggregated α-syn Completed; did not meet primary or secondary outcomes; Phase II terminated BIIB054/α-syn complex formation Brys et al. (2019)
Passive MEDI1341/Astra Zeneca Intravenous infusion Targets monomeric and aggregated aSyn Phase I is ongoing Currently unavailable Schofield et al. (2019)
Active UB-312 Intramuscular injection Targets aggregated aSyn Phase I is ongoing Currently unavailable Nimmo et al. (2020)